Clinical trial
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
NCT00021463 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00021463 |
|---|---|
| Title | Changing to Nonprotease Inhibitor Treatment to Improve Side Effects |
| Official title | Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Lipodystrophy |
| Intervention type | Drug |
| Interventions | Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz, Nevirapine |
| Enrollment | 342 |
| Primary completion | Feb 1, 2002 |
| First posted | Aug 31, 2001 |
| Last update posted | Feb 28, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: